1. Home
  2. MDWD vs DC Comparison

MDWD vs DC Comparison

Compare MDWD & DC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MDWD
  • DC
  • Stock Information
  • Founded
  • MDWD 2000
  • DC 2017
  • Country
  • MDWD Israel
  • DC United States
  • Employees
  • MDWD N/A
  • DC N/A
  • Industry
  • MDWD Medicinal Chemicals and Botanical Products
  • DC Precious Metals
  • Sector
  • MDWD Health Care
  • DC Basic Materials
  • Exchange
  • MDWD Nasdaq
  • DC Nasdaq
  • Market Cap
  • MDWD 184.8M
  • DC 209.6M
  • IPO Year
  • MDWD 2014
  • DC N/A
  • Fundamental
  • Price
  • MDWD $20.15
  • DC $2.45
  • Analyst Decision
  • MDWD Strong Buy
  • DC Buy
  • Analyst Count
  • MDWD 1
  • DC 1
  • Target Price
  • MDWD $25.00
  • DC $6.00
  • AVG Volume (30 Days)
  • MDWD 78.0K
  • DC 235.1K
  • Earning Date
  • MDWD 03-20-2025
  • DC 03-27-2025
  • Dividend Yield
  • MDWD N/A
  • DC N/A
  • EPS Growth
  • MDWD N/A
  • DC N/A
  • EPS
  • MDWD N/A
  • DC N/A
  • Revenue
  • MDWD $19,720,000.00
  • DC N/A
  • Revenue This Year
  • MDWD $10.15
  • DC N/A
  • Revenue Next Year
  • MDWD $25.62
  • DC N/A
  • P/E Ratio
  • MDWD N/A
  • DC N/A
  • Revenue Growth
  • MDWD N/A
  • DC N/A
  • 52 Week Low
  • MDWD $11.04
  • DC $1.84
  • 52 Week High
  • MDWD $24.00
  • DC $3.25
  • Technical
  • Relative Strength Index (RSI)
  • MDWD 57.75
  • DC 64.96
  • Support Level
  • MDWD $18.73
  • DC $2.23
  • Resistance Level
  • MDWD $19.73
  • DC $2.37
  • Average True Range (ATR)
  • MDWD 0.78
  • DC 0.08
  • MACD
  • MDWD 0.02
  • DC 0.00
  • Stochastic Oscillator
  • MDWD 66.35
  • DC 97.83

About MDWD MediWound Ltd.

MediWound Ltd is an integrated biopharmaceutical company focused on developing, manufacturing, and commercializing novel therapeutic products to address unmet medical needs in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders, and other indications. Its first biopharmaceutical product, NexoBrid is an FDA-approved orphan biologic for eschar removal in severe burns that can replace surgical interventions and minimize associated costs and complications. Its other product candidates in different stages of the pipeline include EscharEx for debridement of chronic wounds, and MW005 for the treatment of non-melanoma skin cancer. The company derives a majority of its revenue from the United States and the rest from the EU and other international markets.

About DC Dakota Gold Corp.

Dakota Gold Corp is a gold exploration and development company with a specific focus on revitalizing the Homestake District in Lead, South Dakota. Dakota Gold has high-caliber gold mineral properties covering over 48 thousand acres surrounding the historic Homestake Mine.

Share on Social Networks: